Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentGuruFocus · 1 day ago
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPRNewsWire · 1 day ago
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentBusiness Wire · 1 day ago
Summit Expands Ivonescimab Development Into Biliary Tract CancerZacks Investment Research · 2 days ago
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026Business Wire · 2 days ago
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Zacks Investment Research · 3 days agoSummit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 23, 2026 | -$0.27 | -$0.28 | Miss |
| Apr 30, 2026 | -$0.33 | -$0.24 | Beat |
| Feb 23, 2026 | -$0.10 | -$0.29 | Miss |
| Oct 20, 2025 | -$0.18 | -$0.31 | Miss |
| Aug 11, 2025 | -$0.09 | -$0.76 | Miss |
| May 1, 2025 | -$0.09 | -$0.09 | Beat |